Inactive Instrument

Polydex Pharmaceuticals Limited

POLXF

BS7317282002

Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2019

May 01, 2019 at 08:58 am

Polydex Pharmaceuticals Limited announced earnings results for the full year ended January 31, 2019. For the full year, the company announced sales was USD 4.942 million compared to USD 5.279 million a year ago. Net income was USD 230,946 compared to USD 448,005 a year ago. Basic earnings per share was USD 0.07 compared to USD 0.13 a year ago.

Latest news about Polydex Pharmaceuticals Limited

Biospectra, Inc. and BioSpectra Canada, Ltd completed the acquisition of Polydex Pharmaceuticals Limited (OTCPK:POLX.F).	08/08/23	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2023	15/06/23	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2023	02/05/23	CI
Biospectra, Inc. and BioSpectra Canada, Ltd entered into an agreement to acquire Polydex Pharmaceuticals Limited (OTCPK:POLX.F) for $6.9 million.	26/04/23	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	15/12/22	CI
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Revenue $858,089	15/12/22	MT
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q3 Loss $-0.11	15/12/22	MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended July 31, 2022	15/09/22	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2022	15/06/22	CI
Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Posts Q1 Revenue $1.2M	15/06/22	MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022	02/05/22	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2022	02/05/22	CI
Polydex Pharmaceuticals Limited Enters into an Agreement with Termanox Water Treatment Solutions for A Novel Use of Its Native Dextran Product	26/01/22	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	15/12/21	CI
Polydex Pharmaceuticals : Earnings Flash (POLXF) POLYDEX PHARMACEUTICALS LIMITED Reports Q2 Revenue $1.34M	15/09/21	MT
Polydex Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended April 30, 2021	15/06/21	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2021	30/04/21	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2020	28/04/20	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended October 31, 2019	15/12/19	CI
Polydex Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2019	15/09/19	CI
Polydex Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended January 31, 2019	01/05/19	CI
Polydex Pharmaceuticals Limited Announces Executive Changes	17/12/18	CI
Polydex Pharmaceuticals Limited Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended Oct. 31, 2018	17/12/18	CI
Polydex Pharmaceuticals Limited Announces Earnings Results for the Second Quarter and Six Months Ended July 31, 2018	19/09/18	CI
Polydex Pharmaceuticals Limited Announces Earnings Results for the First Quarter Ended April 30, 2018	15/06/18	CI

Chart Polydex Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Polydex Pharmaceuticals Limited is a company, which is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company's products include Iron Dextran and Dextran Sulphate. The Company sells Iron Dextran to independent distributors and wholesalers primarily in Europe, the Far East, South America and Canada. Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors, or direct to companies in the United States and Europe for analytical applications.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals